PPARγ protein evidenced in gastric adenocarcinoma specimens and PPARγ agonists show dose-dependent inhibitory effects on the proliferation of gastric cancer cell lines
PPARγ underexpression is detected in a number of colorectal cancer patients, and epigenetic silencing of PPARγ is a biomarker for colorectal cancer progression and adverse patients' outcome
PPARγ epigenetic silencing is coordinated by UHRF1 mediating colorectal cancer progression, and a significant low PPARγ expression is associated with distant metastases and reduced patients’ survival